Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. It doesn’t happen often. At the 2011 National Prayer Breakfast in ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...

Add Yahoo as a preferred source to see more of our stories on Google. -Credit:20th Century Fox/Getty Images (20th Century Fox/Getty Images) A war hammer used by Mel Gibson in his portrayal of William ...

Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease ...

Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...

The Dundee girl’s story is now cast in the same template. Instead of English oppressors, the bogeyman is immigration. Instead of Mel Gibson bellowing “They may take our lives, but they’ll never take ...